We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pyrukynd is also being reviewed by the European Medicines Agency for treating adults with pyruvate kinase deficiency, and a regulatory decision is expected by the end of 2022. Read More
Newly confirmed and sworn-in FDA Commissioner Robert Califf spelled out some of his priorities in a Feb. 17 memo to the agency’s staff and repeated them in a series of tweets from his brand-new Twitter account — @DrCaliff_FDA. Read More
Disappointing pharmacies who have had a beef with pharmacy benefit managers (PBMs) for years, the U.S. Federal Trade Commission voted against beginning an investigation into how PBM drug price negotiating practices affect independent and specialty pharmacies. Read More
Sanofi and Regeneron have stopped their investigation of Dupixent (dupilumab) as a treatment for chronic spontaneous urticaria (CSU) in patients who don’t respond to Genentech’s Xolair (omalizumab). Read More
A patient death has prompted Atara Biotherapeutics to issue a voluntary hold on patient recruitment into its potentially groundbreaking phase 1 trial of the CAR-T cell therapy ATA2271 for pleural mesothelioma, an untreatable cancer. Read More
Amgen has become the latest company to discontinue development of an obesity drug candidate from what had been an emerging class of medicines based on growth/differentiation factor-15 (GDF-15) protein. Read More
Collins and Nelson will help oversee the creation of the Advanced Research Projects Agency for Health, which will research treatments for serious ailments, including cancers, infectious diseases and Alzheimer’s disease. Read More